#METABOLOMICS WORKBENCH RMbeach1053_20221121_093934 DATATRACK_ID:3589 STUDY_ID:ST002354 ANALYSIS_ID:AN003845 PROJECT_ID:PR001511 VERSION 1 CREATED_ON November 22, 2022, 5:53 am #PROJECT PR:PROJECT_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. PR:PROJECT_SUMMARY Comprehensive analysis of the lipidomic changes resulting from feeding with a PR:PROJECT_SUMMARY over EPA analogue alone, and in combination with the NSAID naproxen. PR:INSTITUTE UConn Health PR:DEPARTMENT Center for Molecular Oncology PR:LABORATORY Rosenberg Laboratory PR:LAST_NAME Beach PR:FIRST_NAME Ryan PR:ADDRESS 263 Farmington Avenue, Farmington, Connecticut, 06030, USA PR:EMAIL rbeach@uchc.edu PR:PHONE 860-679-8703 PR:FUNDING_SOURCE NCI PREVENT funding #STUDY ST:STUDY_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. ST:STUDY_SUMMARY Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in ST:STUDY_SUMMARY the United States. Patients with the genetic disorder Familial Adenomatous ST:STUDY_SUMMARY Polyposis (FAP) develop hundreds to thousands of polyps that unless removed by ST:STUDY_SUMMARY prophylactic colectomy will progress to CRC at an early age. Non-steroidal ST:STUDY_SUMMARY anti-inflammatory drugs (NSAIDs) and -3 marine polyunsaturated fatty acids ST:STUDY_SUMMARY (PUFA), such as eicosapentaenoic acid (EPA), have been evaluated for their ST:STUDY_SUMMARY chemopreventive potential in delaying the onset of CRC in high-risk patients. In ST:STUDY_SUMMARY this study, we determined whether the NSAID, naproxen, alone or in combination ST:STUDY_SUMMARY with a chemically-stable form of EPA (TP-252), affects tumor formation in the ST:STUDY_SUMMARY ApcPirc rat model. When compared to control diet, animals fed naproxen or HD ST:STUDY_SUMMARY TP-252 had 66%, and 82% fewer tumors respectively. However, when fed a ST:STUDY_SUMMARY combination of naproxen and HD TP-252, animals exhibited a 95% reduction in ST:STUDY_SUMMARY tumor formation and a 98% reduction in tumor volume, respectively. To elucidate ST:STUDY_SUMMARY potential mechanisms of tumor protection, a comprehensive, targeted lipidomic ST:STUDY_SUMMARY analysis was performed on colonic mucosa to determine changes in eicosanoid ST:STUDY_SUMMARY metabolism. Animals receiving TP-252 alone or in combination with naproxen had ST:STUDY_SUMMARY significantly reduced mucosal levels of pro-inflammatory -6 eicosanoids ST:STUDY_SUMMARY (PGE2, 5-HETE, and 14,15-DiHETrE), along with a simultaneous increase in ST:STUDY_SUMMARY anti-inflammatory EPA-derived -3 eicosanoids. Our colonic mucosal lipidomic ST:STUDY_SUMMARY analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers, ST:STUDY_SUMMARY including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were increased in both ST:STUDY_SUMMARY the tissue and plasma of rats receiving TP-252 and were significantly correlated ST:STUDY_SUMMARY with tumor protection. Further studies with this drug combination should be ST:STUDY_SUMMARY focused on dose optimization and the role of EPA-derived lipid mediators in CRC ST:STUDY_SUMMARY initiation and progression. ST:INSTITUTE UConn Health ST:LAST_NAME Beach ST:FIRST_NAME Ryan ST:ADDRESS 263 Farmington Avenue, Farmington CT 06030 ST:EMAIL rbeach@uchc.edu ST:PHONE 860-679-8703 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 SU:AGE_OR_AGE_RANGE 26 weeks of age SU:WEIGHT_OR_WEIGHT_RANGE 320-460 grams SU:GENDER Male SU:ANIMAL_ANIMAL_SUPPLIER RRRC (University of Missouri) SU:ANIMAL_HOUSING Center for Comparative Medicine UConn SU:ANIMAL_FEED Modified AIN-93G diet from Research Diets SU:ANIMAL_WATER ab libitum #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS 2440 TFA-T1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T1.wiff SUBJECT_SAMPLE_FACTORS 2443 TFA-T2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T2.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-T3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T3.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-T4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T4.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-T5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T5.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-T6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T6.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-T7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T7.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-T8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T8.wiff SUBJECT_SAMPLE_FACTORS 2446 TFA-T9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T9.wiff SUBJECT_SAMPLE_FACTORS 2336 TFA-T10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T10.wiff SUBJECT_SAMPLE_FACTORS 2850 TFA-T11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T11.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T12.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T13.wiff SUBJECT_SAMPLE_FACTORS 3099 TFA-T14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T14.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-T15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T15.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-T16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T16.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-T17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T17.wiff SUBJECT_SAMPLE_FACTORS 2901 TFA-T18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T18.wiff SUBJECT_SAMPLE_FACTORS 2903 TFA-T19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T19.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-T20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T20.wiff SUBJECT_SAMPLE_FACTORS 3021 TFA-T21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T21.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-T22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T22.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-T23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T23.wiff SUBJECT_SAMPLE_FACTORS 2454 TFA-T24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T24.wiff SUBJECT_SAMPLE_FACTORS 2884 TFA-T25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T25.wiff SUBJECT_SAMPLE_FACTORS 2885 TFA-T26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T26.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-T27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-T28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-T29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-T30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T30.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-T31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T31.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-T32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T32.wiff SUBJECT_SAMPLE_FACTORS 2878 TFA-T33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T33.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-T34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T34.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-T35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T35.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-T36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T36.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-T37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T37.wiff SUBJECT_SAMPLE_FACTORS 2747 TFA-T38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T38.wiff SUBJECT_SAMPLE_FACTORS 2899 TFA-T39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T39.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-T40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T40.wiff SUBJECT_SAMPLE_FACTORS 3029 TFA-T41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T41.wiff SUBJECT_SAMPLE_FACTORS 3030 TFA-T42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T42.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-T43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T43.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-T44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T44.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-T45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T45.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-T46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T46.wiff SUBJECT_SAMPLE_FACTORS 2854 TFA-T47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T47.wiff SUBJECT_SAMPLE_FACTORS 3024 TFA-T48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T48.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-T49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T49.wiff SUBJECT_SAMPLE_FACTORS 3102 TFA-T50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T50.wiff SUBJECT_SAMPLE_FACTORS 3104 TFA-T51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T51.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-T52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T52.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-T53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T53.wiff SUBJECT_SAMPLE_FACTORS 2844 TFA-T54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T54.wiff SUBJECT_SAMPLE_FACTORS 2845 TFA-T55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T55.wiff SUBJECT_SAMPLE_FACTORS 2846 TFA-T56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T56.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoT1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT1.wiff SUBJECT_SAMPLE_FACTORS 2443 EicoT2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT2.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoT3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT3.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoT4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT4.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoT5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT5.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoT6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT6.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoT7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT7.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoT8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT8.wiff SUBJECT_SAMPLE_FACTORS 2446 EicoT9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT9.wiff SUBJECT_SAMPLE_FACTORS 2336 EicoT10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT10.wiff SUBJECT_SAMPLE_FACTORS 2850 EicoT11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT11.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT12.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT13.wiff SUBJECT_SAMPLE_FACTORS 3099 EicoT14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT14.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoT15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT15.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoT16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT16.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoT17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT17.wiff SUBJECT_SAMPLE_FACTORS 2901 EicoT18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT18.wiff SUBJECT_SAMPLE_FACTORS 2903 EicoT19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT19.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoT20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT20.wiff SUBJECT_SAMPLE_FACTORS 3021 EicoT21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT21.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoT22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT22.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoT23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT23.wiff SUBJECT_SAMPLE_FACTORS 2454 EicoT24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT24.wiff SUBJECT_SAMPLE_FACTORS 2884 EicoT25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT25.wiff SUBJECT_SAMPLE_FACTORS 2885 EicoT26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT26.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoT27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoT28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoT29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoT30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT30.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoT31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT31.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoT32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT32.wiff SUBJECT_SAMPLE_FACTORS 2878 EicoT33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT33.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoT34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT34.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoT35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT35.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoT36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT36.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoT37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT37.wiff SUBJECT_SAMPLE_FACTORS 2747 EicoT38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT38.wiff SUBJECT_SAMPLE_FACTORS 2899 EicoT39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT39.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoT40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT40.wiff SUBJECT_SAMPLE_FACTORS 3029 EicoT41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT41.wiff SUBJECT_SAMPLE_FACTORS 3030 EicoT42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT42.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoT43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT43.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoT44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT44.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoT45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT45.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoT46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT46.wiff SUBJECT_SAMPLE_FACTORS 2854 EicoT47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT47.wiff SUBJECT_SAMPLE_FACTORS 3024 EicoT48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT48.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoT49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT49.wiff SUBJECT_SAMPLE_FACTORS 3102 EicoT50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT50.wiff SUBJECT_SAMPLE_FACTORS 3104 EicoT51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT51.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoT52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT52.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoT53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT53.wiff SUBJECT_SAMPLE_FACTORS 2844 EicoT54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT54.wiff SUBJECT_SAMPLE_FACTORS 2845 EicoT55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT55.wiff SUBJECT_SAMPLE_FACTORS 2846 EicoT56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT56.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-P1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P1.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-P2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P2.wiff SUBJECT_SAMPLE_FACTORS 2442 TFA-P3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P3.wiff SUBJECT_SAMPLE_FACTORS 2440 TFA-P4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P4.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-P5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P5.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-P6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P6.wiff SUBJECT_SAMPLE_FACTORS 3190 TFA-P7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P7.wiff SUBJECT_SAMPLE_FACTORS 2165 TFA-P8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P8.wiff SUBJECT_SAMPLE_FACTORS 2167 TFA-P9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P9.wiff SUBJECT_SAMPLE_FACTORS 2168 TFA-P10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P10.wiff SUBJECT_SAMPLE_FACTORS 2333 TFA-P11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P11.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-P12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P12.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-P13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P13.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-P14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P14.wiff SUBJECT_SAMPLE_FACTORS 2264 TFA-P15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P15.wiff SUBJECT_SAMPLE_FACTORS 2267 TFA-P16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P16.wiff SUBJECT_SAMPLE_FACTORS 2265 TFA-P17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P17.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-P18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P18.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-P19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P19.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-P20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P20.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-P21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P21.wiff SUBJECT_SAMPLE_FACTORS 2170 TFA-P22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P22.wiff SUBJECT_SAMPLE_FACTORS 2169 TFA-P23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P23.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-P24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P24.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-P25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P25.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-P26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P26.wiff SUBJECT_SAMPLE_FACTORS 2284 TFA-P27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-P28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-P29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-P30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P30.wiff SUBJECT_SAMPLE_FACTORS 2352 TFA-P31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P31.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-P32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P32.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-P33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P33.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-P34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P34.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-P35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P35.wiff SUBJECT_SAMPLE_FACTORS 2171 TFA-P36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P36.wiff SUBJECT_SAMPLE_FACTORS 2174 TFA-P37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P37.wiff SUBJECT_SAMPLE_FACTORS 2175 TFA-P38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P38.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-P39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P39.wiff SUBJECT_SAMPLE_FACTORS 2387 TFA-P40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P40.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-P41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P41.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-P42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P42.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-P43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P43.wiff SUBJECT_SAMPLE_FACTORS 2394 TFA-P44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P44.wiff SUBJECT_SAMPLE_FACTORS 2398 TFA-P45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P45.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-P46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P46.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-P47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P47.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-P48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P48.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-P49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P49.wiff SUBJECT_SAMPLE_FACTORS 2177 TFA-P50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P50.wiff SUBJECT_SAMPLE_FACTORS 2180 TFA-P51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P51.wiff SUBJECT_SAMPLE_FACTORS 2384 TFA-P52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P52.wiff SUBJECT_SAMPLE_FACTORS 2389 TFA-P53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P53.wiff SUBJECT_SAMPLE_FACTORS 2391 TFA-P54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P54.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-P55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P55.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-P56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P56.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoP1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP1.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoP2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP2.wiff SUBJECT_SAMPLE_FACTORS 2442 EicoP3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP3.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoP4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP4.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoP5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP5.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoP6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP6.wiff SUBJECT_SAMPLE_FACTORS 3190 EicoP7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP7.wiff SUBJECT_SAMPLE_FACTORS 2165 EicoP8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP8.wiff SUBJECT_SAMPLE_FACTORS 2167 EicoP9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP9.wiff SUBJECT_SAMPLE_FACTORS 2168 EicoP10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP10.wiff SUBJECT_SAMPLE_FACTORS 2333 EicoP11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP11.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoP12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP12.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoP13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP13.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoP14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP14.wiff SUBJECT_SAMPLE_FACTORS 2264 EicoP15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP15.wiff SUBJECT_SAMPLE_FACTORS 2267 EicoP16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP16.wiff SUBJECT_SAMPLE_FACTORS 2265 EicoP17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP17.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoP18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP18.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoP19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP19.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoP20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP20.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoP21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP21.wiff SUBJECT_SAMPLE_FACTORS 2170 EicoP22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP22.wiff SUBJECT_SAMPLE_FACTORS 2169 EicoP23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP23.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoP24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP24.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoP25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP25.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoP26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP26.wiff SUBJECT_SAMPLE_FACTORS 2284 EicoP27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoP28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoP29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoP30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP30.wiff SUBJECT_SAMPLE_FACTORS 2352 EicoP31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP31.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoP32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP32.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoP33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP33.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoP34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP34.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoP35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP35.wiff SUBJECT_SAMPLE_FACTORS 2171 EicoP36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP36.wiff SUBJECT_SAMPLE_FACTORS 2174 EicoP37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP37.wiff SUBJECT_SAMPLE_FACTORS 2175 EicoP38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP38.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoP39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP39.wiff SUBJECT_SAMPLE_FACTORS 2387 EicoP40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP40.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoP41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP41.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoP42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP42.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoP43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP43.wiff SUBJECT_SAMPLE_FACTORS 2394 EicoP44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP44.wiff SUBJECT_SAMPLE_FACTORS 2398 EicoP45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP45.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoP46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP46.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoP47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP47.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoP48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP48.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoP49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP49.wiff SUBJECT_SAMPLE_FACTORS 2177 EicoP50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP50.wiff SUBJECT_SAMPLE_FACTORS 2180 EicoP51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP51.wiff SUBJECT_SAMPLE_FACTORS 2384 EicoP52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP52.wiff SUBJECT_SAMPLE_FACTORS 2389 EicoP53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP53.wiff SUBJECT_SAMPLE_FACTORS 2391 EicoP54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP54.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoP55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP55.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoP56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP56.wiff #COLLECTION CO:COLLECTION_SUMMARY Animals were sacrificed by CO2 narcosis, and large intestines were excised, CO:COLLECTION_SUMMARY washed with ice-cold PBS, and laid flat on filter paper. Tumor-adjacent CO:COLLECTION_SUMMARY full-thickness colon segments were flash-frozen in liquid Nitrogen and stored at CO:COLLECTION_SUMMARY -80C until analysis. Blood was collected via cardiac puncture and put in lithium CO:COLLECTION_SUMMARY heparin tubes on ice. Samples were centrifuged at 2,000 g for 20 minutes, and CO:COLLECTION_SUMMARY supernatant (plasma) was collected and stored at -80C until analysis. CO:SAMPLE_TYPE Blood (Plasma) and Large Intestine #TREATMENT TR:TREATMENT_SUMMARY Rats were fed two doses of TP-252 equivalent to consuming 1.3 and 2.6 g/kg/day TR:TREATMENT_SUMMARY for LD TP-252 and HD TP-252, respectively. Alternatively, rats were also fed a TR:TREATMENT_SUMMARY diet containing 2% EPA-FFA in their diet (equivalent to 1.14 g/kg/day of EPA). TR:TREATMENT_SUMMARY In groups receiving naproxen, the dose of naproxen was 11.4 mg/kg/day, or TR:TREATMENT_SUMMARY roughly 4 mg/rat/day. These treatment groups were carried out for the 20 weeks, TR:TREATMENT_SUMMARY and then animals were sacrificed and tissue collected and analyzed. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples (0.85 ml) were spiked with 5 ng each (in 150 μl methanol) of SP:SAMPLEPREP_SUMMARY 15(S)-HETE-d8,14(15)-EpETrE-d11, Resolvin D2-d5, Leukotriene B4-d4, and SP:SAMPLEPREP_SUMMARY Prostaglandin E1-d4 as internal standards for recovery and quantitation and SP:SAMPLEPREP_SUMMARY mixed thoroughly. The samples were then extracted for PUFA metabolites using C18 SP:SAMPLEPREP_SUMMARY extraction columns as described earlier [1-4]. Briefly, the internal standard SP:SAMPLEPREP_SUMMARY spiked samples were applied to conditioned C18 cartridges, washed with 15% SP:SAMPLEPREP_SUMMARY methanol in water followed by hexane and dried under vacuum. The cartridges were SP:SAMPLEPREP_SUMMARY eluted with 0.5 ml methanol. The eluate was dried under a gentle stream of SP:SAMPLEPREP_SUMMARY nitrogen. The residue was redissolved in 50 μl methanol-25 mM aqueous ammonium SP:SAMPLEPREP_SUMMARY acetate (1:1) and subjected to LC-MS analysis. SP:SAMPLEPREP_PROTOCOL_FILENAME Methods of Eicosanoid Detection.pdf #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3μ, CH:CHROMATOGRAPHY_SUMMARY 2.1x150 mm) column. The mobile phase consisted of a gradient between A: CH:CHROMATOGRAPHY_SUMMARY methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile CH:CHROMATOGRAPHY_SUMMARY (90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with CH:CHROMATOGRAPHY_SUMMARY respect to the composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%; CH:CHROMATOGRAPHY_SUMMARY 8-15 min, 80-95%; and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC CH:CHROMATOGRAPHY_SUMMARY eluate was directly introduced to ESI source of QTRAP5500 mass analyzer CH:CHROMATOGRAPHY_SUMMARY (ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35 CH:CHROMATOGRAPHY_SUMMARY psi, GS1: 35 psi, GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V, CH:CHROMATOGRAPHY_SUMMARY Collision gas: low, Declustering Potential: -60 V, and Entrance Potential: -7 V. CH:CHROMATOGRAPHY_SUMMARY The eluate was monitored by Multiple Reaction Monitoring method to detect unique CH:CHROMATOGRAPHY_SUMMARY molecular ion – daughter ion combinations for each of the lipid mediators CH:CHROMATOGRAPHY_SUMMARY using a scheduled MRM around the expected retention time for each compound. CH:CHROMATOGRAPHY_SUMMARY Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials CH:CHROMATOGRAPHY_SUMMARY (7 – 10 V) were used for each MRM transition. Spectra of each peak detected in CH:CHROMATOGRAPHY_SUMMARY the scheduled MRM were recorded using Enhanced Product Ion scan to confirm the CH:CHROMATOGRAPHY_SUMMARY structural identity. The data was collected using Analyst 1.6.2 software and the CH:CHROMATOGRAPHY_SUMMARY MRM transition chromatograms were quantitated by MultiQuant software (both from CH:CHROMATOGRAPHY_SUMMARY ABSCIEX). The internal standard signals in each chromatogram were used for CH:CHROMATOGRAPHY_SUMMARY normalization, recovery, as well as relative quantitation of each analyte. CH:CHROMATOGRAPHY_TYPE None (Direct infusion) CH:INSTRUMENT_NAME Prominence XR CH:COLUMN_NAME Luna C18 (3u, 2.1x150 mm) column CH:FLOW_RATE 0.2ml/min #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME ABI Sciex 5500 QTrap MS:INSTRUMENT_TYPE QTRAP MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS Mass spectra for each detected lipid metabolite were recorded using the enhanced MS:MS_COMMENTS production feature to verify the identity of the detected peak. Data were MS:MS_COMMENTS collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX) MS:MS_COMMENTS software, respectively. Correction for recovery efficiencies and relative MS:MS_COMMENTS quantitation of each analyte were performed using signals from each chromatogram MS:MS_COMMENTS corresponding to the spiked-in internal standards. Under standardized conditions MS:MS_COMMENTS of liquid chromatography-mass spectrometry quantitation, the detection limits MS:MS_COMMENTS for the eicosanoids are 1–2 pg on the column and the limit of quantitation is MS:MS_COMMENTS 5 pg at a signal-to-noise ratio of 3. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS ng/mL MS_METABOLITE_DATA_START Samples EicoP1 EicoP2 EicoP3 EicoP4 EicoP5 EicoP6 EicoP7 EicoP8 EicoP9 EicoP10 EicoP11 EicoP12 EicoP13 EicoP14 EicoP15 EicoP16 EicoP17 EicoP18 EicoP19 EicoP20 EicoP21 EicoP22 EicoP23 EicoP24 EicoP25 EicoP26 EicoP27 EicoP28 EicoP29 EicoP30 EicoP31 EicoP32 EicoP33 EicoP34 EicoP35 EicoP36 EicoP37 EicoP38 EicoP39 EicoP40 EicoP41 EicoP42 EicoP43 EicoP44 EicoP45 EicoP46 EicoP47 EicoP48 EicoP49 EicoP50 EicoP51 EicoP52 EicoP53 EicoP54 EicoP55 EicoP56 Factors Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma 13,14dhPGE1 0.013 13,14dh-15k-PGE1 0.078 0.090 0.139 0.115 D17-PGE1 PGE1 0.326 0.462 0.485 0.571 0.115 0.289 0.201 0.322 0.336 0.474 0.252 0.257 0.215 0.571 0.404 0.331 0.201 0.123 0.109 0.179 0.114 0.369 0.183 0.320 0.567 15(R)-PGE1 0.361 15-keto PGE1 Bicyclo PGE1 0.071 0.149 0.165 0.242 0.164 0.282 0.223 0.298 0.182 0.346 0.276 0.147 0.208 0.259 0.409 0.199 0.164 0.143 0.146 0.248 0.225 0.254 19(R)-hydroxy PGE1 0.152 0.121 0.170 0.175 0.255 0.203 0.117 2,3-dinor PGE1 PGE2 11.313 11.022 13.092 14.319 4.942 7.165 3.593 1.518 9.854 7.151 14.250 17.775 20.986 18.308 5.230 5.819 7.351 6.718 7.035 5.240 5.840 4.804 12.677 6.636 7.378 14.386 9.288 8.585 2.471 10.232 4.449 10.016 4.906 6.616 5.796 3.645 3.298 5.208 6.550 2.539 2.134 3.207 6.040 5.666 8.768 5.774 4.496 7.961 8.876 11.374 10.831 12.605 18.911 14.177 9.139 11.692 15-keto PGE2 0.254 0.489 0.297 0.185 0.251 0.233 0.180 0.254 0.991 0.234 2.353 0.213 0.307 13,14dh-15k-PGE2 0.620 0.500 0.762 0.679 0.381 0.227 0.654 0.908 1.265 0.896 1.139 1.445 0.803 1.921 1.707 1.671 0.642 1.439 1.839 4.782 4.015 2.678 1.508 0.760 1.933 1.696 2.102 1.044 1.590 1.712 1.820 1.711 1.585 1.619 2.005 0.899 0.770 1.802 2.576 2.620 2.903 2.256 1.312 1.039 1.599 1.490 Bicyclo PGE2 0.474 0.578 0.904 0.940 0.268 0.481 0.295 0.388 0.975 0.945 0.790 3.945 4.479 3.839 5.892 7.237 5.183 2.376 6.489 10.517 7.250 6.171 6.316 5.338 7.871 2.613 6.887 1.444 7.051 3.287 6.098 3.386 9.978 9.731 9.667 6.385 3.041 3.880 3.183 2.364 3.485 3.303 2.946 3.774 3.355 5.254 6.183 4.992 PGA2 11.253 19.041 19.217 22.413 9.711 3.317 7.810 1.699 17.540 9.798 14.001 22.222 23.848 19.827 25.397 29.027 27.432 35.898 41.665 39.845 20.482 37.514 56.372 43.367 38.798 46.555 37.134 45.258 16.543 50.354 13.726 44.435 23.387 33.549 39.098 21.515 57.080 60.940 44.887 40.266 20.627 25.532 25.362 19.318 24.342 22.245 22.558 21.731 30.290 19.791 35.241 42.851 33.899 35.489 37.861 43.405 tetranor PGEM 0.031 0.027 0.020 0.029 0.044 0.022 0.025 0.024 0.030 0.026 0.038 0.022 0.027 0.059 0.082 0.067 0.027 PGE3 0.443 0.325 0.718 0.432 0.163 0.518 0.342 0.611 1.699 1.477 2.144 13.969 18.716 19.340 29.828 25.204 27.490 16.993 31.490 79.625 51.694 45.635 78.333 66.182 63.005 9.338 45.164 13.182 37.883 16.352 21.671 25.236 32.131 36.621 46.148 61.007 28.520 21.275 29.384 16.753 12.226 17.058 17.750 15.235 24.595 27.729 36.168 38.185 43.198 24.251 36.039 38.940 40.576 PGD2 0.840 0.855 PGJ2 0.886 0.574 1.114 1.161 0.367 0.576 0.694 0.666 1.019 2.563 0.776 3.178 2.802 4.426 5.310 4.937 1.737 4.974 8.742 6.081 4.854 6.203 4.818 6.500 2.015 5.722 1.053 4.649 2.553 4.069 4.462 2.659 7.906 7.412 6.766 5.184 2.574 2.351 1.665 2.375 2.362 2.132 2.993 2.730 3.799 4.648 3.025 4.191 4.306 4.404 D12-PGJ2 0.247 0.262 0.215 15d-D12,14-PGJ2 0.136 0.107 0.658 0.983 0.527 1.763 0.834 1.322 0.545 0.515 0.921 1.176 2.660 1.798 1.849 0.101 0.739 0.299 1.052 1.380 1.591 0.805 1.052 1.181 0.796 1.056 1.141 1.516 0.716 0.181 0.350 0.655 0.784 1.040 1.113 0.874 1.242 0.891 0.322 0.445 0.833 0.674 13,14dh-15k-PGD2 8.427 7.217 8.733 8.687 3.255 1.221 3.024 0.943 7.758 6.335 9.097 9.287 11.212 9.777 2.718 2.463 3.777 2.795 2.743 2.305 2.077 2.365 6.601 3.205 2.641 1.238 4.032 1.853 4.320 2.447 2.614 3.251 1.656 1.667 2.729 1.186 2.580 2.304 4.114 2.319 1.803 3.158 2.879 4.269 3.583 4.637 7.800 6.026 3.518 4.214 PGD3 3.905 5.216 4.493 7.775 11.291 7.274 8.002 24.170 15.222 13.962 17.406 20.853 17.561 2.501 11.876 14.369 4.362 5.540 8.323 8.843 18.081 7.534 4.595 11.388 4.565 4.172 6.253 3.535 6.172 9.485 9.161 12.813 8.664 7.757 11.310 11.376 15d-D12,14-PGJ3 PGF1a PGF2a 0.403 0.911 15-keto PGF2a 0.355 13,14dh-15k-PGF2a 0.078 0.231 0.134 0.235 0.088 0.109 0.540 0.562 0.141 PGF3a 0.158 iPF-VI 0.848 1.054 1.133 1.715 0.430 0.294 0.384 0.201 1.088 0.684 0.934 1.477 1.703 1.365 0.559 0.601 0.705 0.542 0.570 0.351 0.322 0.360 1.108 0.274 0.329 0.543 0.325 0.418 0.172 0.946 0.300 0.873 0.327 0.428 0.543 0.275 0.158 0.317 0.406 0.085 0.123 0.207 0.617 0.509 1.032 0.456 0.433 0.456 0.512 1.125 0.686 0.974 0.882 1.164 0.503 0.777 6kPGF1a 6-keto PGE1 6,15-diketo PGFa TXB2 2.428 1.801 2.991 1.395 2.628 29.785 0.865 0.083 0.751 0.316 0.742 0.426 0.820 0.953 0.600 1.047 0.790 1.795 0.674 0.468 1.122 0.393 0.720 0.862 0.242 0.320 0.248 0.545 0.165 0.248 0.245 0.229 0.500 0.691 0.395 5.173 0.699 1.427 0.882 0.319 0.147 11dh-TXB2 0.212 0.183 0.166 0.247 0.074 0.133 0.303 0.381 0.143 0.200 0.131 0.247 0.133 0.400 0.269 2,3-dinor TXB2 0.067 0.039 0.124 0.251 0.093 0.122 0.105 11dh-2,3-dinor TXB2 0.033 0.048 0.159 0.020 TXB3 1.197 1.392 0.798 0.321 2.237 0.524 1.269 0.610 0.756 0.948 1.103 0.577 1.008 1.324 0.822 0.729 0.660 0.460 0.936 0.779 0.971 0.989 11dh TXB3 0.370 LTB4 12-OxoLTB4 0.115 0.107 0.189 0.359 0.050 0.073 0.115 0.037 0.177 0.440 0.212 0.494 1.134 0.624 0.783 0.283 0.758 1.173 0.765 1.495 1.806 0.867 0.935 0.326 0.847 1.218 1.350 0.296 1.039 0.707 0.721 0.883 0.835 0.828 1.291 0.273 0.237 0.350 0.292 0.820 1.675 0.839 1.503 0.714 0.437 0.265 0.652 0.480 20-hydroxy LTB4 20-COOH LTB4 0.026 0.025 18-carboxy dinor LTB4 LTB5 2.494 1.950 3.007 3.420 0.217 0.145 0.482 0.090 1.475 0.529 1.549 4.340 3.130 35.303 19.279 46.078 46.860 53.895 34.577 15.295 48.143 102.798 60.874 51.045 56.457 46.648 47.286 27.752 57.548 11.431 60.585 19.820 46.294 37.521 49.045 76.884 49.145 62.837 46.519 41.296 44.324 30.710 34.325 47.840 36.109 26.462 37.688 47.257 78.543 58.777 42.971 60.043 45.609 45.650 5(S),6(S)-DiHETE 0.067 0.141 5(S),12(S)-DiHETE 0.719 2.780 0.283 0.718 0.189 0.148 0.158 0.260 0.298 0.135 0.153 5(S),15(S)-DiHETE 5.720 7.187 8.066 13.848 2.070 0.499 1.384 0.302 6.064 3.676 6.410 9.755 9.455 6.881 3.426 3.339 4.338 2.873 3.312 2.360 1.631 1.937 6.435 1.621 1.983 2.019 1.066 2.106 1.495 5.323 2.148 4.545 1.307 2.422 3.436 1.652 1.366 1.465 2.833 0.780 0.562 1.229 2.643 3.299 6.548 3.056 1.952 1.750 2.735 5.269 2.876 6.246 6.813 6.691 2.934 5.877 8(S),15(S)-DiHETE 5.749 7.204 10.367 9.991 2.093 1.297 0.434 6.519 3.251 4.430 10.942 12.732 8.167 2.070 4.375 2.962 2.957 3.263 3.101 1.359 1.915 4.798 1.645 1.618 2.029 2.185 1.876 1.193 3.998 1.315 4.206 2.130 3.156 3.473 1.260 1.129 0.905 1.545 0.705 0.760 1.353 1.552 1.393 3.277 1.856 1.438 2.054 2.641 4.660 2.350 3.235 9.543 4.528 2.529 3.115 5(S),15(S)-DiHEPE 0.233 0.266 0.099 0.430 9-HODE 153.456 156.464 419.945 13-HODE 3520.133 2038.728 3698.836 2083.168 1701.710 782.817 986.097 754.654 2349.902 1608.362 1476.822 3514.014 3690.237 3230.065 3170.431 4746.062 2485.755 3368.519 4077.759 4487.247 2498.758 1993.329 3904.013 2398.883 2789.909 3001.951 3173.736 2435.767 949.062 4900.194 1382.080 4704.728 3163.286 3469.492 3963.880 2042.721 2897.004 2556.533 2798.108 2401.683 1422.361 2234.054 1459.228 1525.837 1530.984 1698.587 1914.953 3415.281 3299.895 2721.794 2858.784 3154.891 2454.443 2583.849 2825.028 3609.430 9(S)-HOTrE 234.357 142.276 237.027 115.303 95.488 20.491 48.378 31.371 141.478 89.428 56.620 282.018 245.400 294.539 202.809 253.902 154.326 245.819 288.616 328.302 190.084 93.885 197.894 222.043 209.861 208.404 214.937 186.833 44.103 472.628 69.900 374.131 271.591 287.169 397.402 146.327 214.927 156.586 198.995 172.576 105.656 135.786 54.227 55.688 53.598 108.875 131.606 233.208 194.745 106.709 186.535 200.798 69.084 124.740 257.528 245.664 13(S)-HOTrE 360.396 195.287 338.113 185.187 137.023 55.008 73.352 38.984 221.689 134.268 90.806 369.137 322.251 383.003 255.368 333.087 189.983 312.356 344.459 437.927 228.144 108.082 224.705 273.070 227.213 293.249 240.046 226.389 66.416 532.317 92.650 474.671 335.310 320.581 498.948 144.938 301.111 208.479 253.146 216.285 116.219 187.989 65.327 60.617 74.973 128.464 157.006 260.899 240.395 117.768 226.652 238.520 76.098 149.539 284.451 281.757 13(S)-HOTrE(g) 52.933 46.549 104.690 49.993 27.377 11.341 22.306 12.688 45.823 34.541 28.318 122.855 115.701 74.785 15.330 30.328 13.358 21.222 20.771 26.555 11.511 8.539 10.669 9.063 10.611 8.544 7.463 7.385 1.945 17.487 5.339 18.882 18.991 14.773 27.315 7.246 7.110 7.154 6.523 6.730 5.435 7.254 6.818 7.024 7.603 5.305 10.665 14.900 18.986 10.268 10.789 11.774 11.277 10.658 12.894 14.788 11(R)-HEDE 32.490 17.037 31.476 17.855 6.555 3.352 4.716 2.553 15.082 8.664 6.491 34.825 30.322 34.198 13.246 29.211 9.714 24.556 20.432 34.132 11.123 6.434 20.606 9.594 8.057 11.590 8.659 9.119 2.426 30.349 3.375 26.859 20.432 20.849 27.459 5.435 13.949 9.307 11.499 8.213 3.472 6.364 4.939 4.792 6.261 6.995 7.756 8.953 13.632 13.610 14.611 17.635 5.216 13.873 18.713 17.922 15(S)-HEDE 26.861 15.565 25.822 18.120 5.788 4.486 4.183 1.929 16.174 8.628 7.293 28.948 28.561 29.594 12.152 22.874 9.412 20.923 19.195 28.504 9.364 6.317 16.160 8.608 7.729 10.897 7.872 8.099 2.751 26.402 3.905 23.206 16.440 16.574 22.962 5.822 12.883 8.151 9.854 8.134 3.098 5.808 4.519 4.559 6.169 5.856 7.347 8.095 11.882 9.990 12.716 15.230 4.058 11.282 15.774 15.011 8(S)-HETrE 37.736 28.885 52.337 31.008 9.454 5.648 10.071 5.480 21.001 17.881 17.451 58.851 51.694 55.707 20.328 42.760 20.812 30.824 30.094 37.578 14.328 14.711 29.082 14.250 15.776 18.080 11.041 16.652 4.251 32.319 8.849 31.872 25.587 24.780 39.239 13.191 13.499 10.087 15.493 8.972 7.272 13.096 16.243 14.652 14.644 13.191 15.843 22.097 35.771 46.530 26.320 32.453 10.924 26.239 22.893 25.482 5(S)-HETrE 49.711 48.082 77.193 83.560 9.855 4.998 8.966 3.522 51.825 23.769 38.739 60.328 46.178 30.324 14.493 16.640 18.832 12.743 11.887 11.286 4.402 5.464 9.492 5.855 4.916 5.047 3.638 4.881 4.284 14.782 5.852 13.571 6.106 5.667 11.157 4.657 3.870 5.153 5.907 2.498 2.100 3.623 25.589 39.752 34.349 8.898 7.877 8.731 11.221 15.107 9.473 11.155 9.833 11.901 7.173 9.922 5-HETE 9246.534 3955.575 8289.973 6282.243 1758.316 797.750 1488.030 521.464 7849.725 2570.716 8906.902 3742.905 5023.529 3190.780 2925.891 3567.146 3765.812 2309.480 4332.452 2163.485 1273.916 1318.864 2614.175 1366.426 1407.086 1394.943 898.469 1406.468 973.257 3297.005 1574.923 4170.713 1359.697 1576.891 2663.507 1261.262 1015.534 1460.199 1529.519 797.362 516.887 1021.566 1999.380 4671.533 2582.008 1716.043 4230.195 1434.057 1748.214 2047.663 3105.081 2043.853 3207.863 2221.278 2584.590 8-HETE 536.382 512.284 881.560 667.653 237.724 99.966 158.262 74.587 451.657 308.364 336.976 867.787 962.459 570.368 218.976 368.261 230.761 176.477 220.557 241.240 134.195 110.539 239.713 96.854 96.482 112.554 87.518 111.832 75.849 268.988 85.626 264.230 184.980 180.996 290.652 95.051 87.757 105.146 103.400 70.181 46.595 88.869 110.246 134.344 127.846 116.331 136.115 165.975 193.655 283.529 162.133 236.389 336.797 227.603 182.461 184.775 9-HETE 325.331 281.667 452.002 369.509 148.985 41.446 83.281 41.148 286.398 183.514 158.817 493.313 551.822 304.257 111.182 190.104 115.408 107.191 111.950 135.043 73.595 56.999 112.199 49.192 45.861 57.662 44.660 53.651 39.547 117.794 41.146 134.101 101.177 108.883 151.528 46.176 43.437 39.977 51.725 33.306 28.630 42.849 62.537 66.664 76.418 58.599 69.537 103.382 109.299 154.744 95.852 117.273 213.682 98.667 89.293 98.204 11-HETE 2649.479 2143.478 3997.255 2637.074 1337.557 534.350 920.275 373.997 2191.583 1729.691 1482.876 4591.755 3578.686 2787.386 1124.859 1898.790 1004.978 1058.204 1121.895 1375.362 797.893 606.270 1397.853 571.769 549.056 683.275 482.631 636.579 285.801 1526.047 366.758 1547.292 1062.252 1135.439 1539.030 469.103 561.684 500.514 608.539 376.603 260.743 462.245 619.884 717.160 735.057 739.238 707.402 923.625 1156.152 1643.507 986.033 1495.691 1655.183 1132.279 1058.606 1092.505 12-HETE 1062.044 874.553 1180.828 906.080 542.594 1842.002 319.262 665.999 960.176 918.304 318.811 1041.877 1217.069 905.485 272.924 649.289 252.577 310.206 291.017 383.597 376.259 178.845 516.753 203.108 203.397 265.432 276.537 195.886 85.342 533.880 297.355 526.962 547.838 779.375 475.266 205.861 138.194 148.742 162.757 259.665 331.753 327.646 201.661 235.690 269.427 450.280 230.944 371.144 490.661 1181.893 679.999 646.851 351.410 395.722 315.397 387.422 15-HETE 815.879 765.608 1155.247 805.062 511.686 258.800 314.068 141.883 823.336 627.120 525.490 1239.617 1393.574 849.954 323.325 500.749 328.656 288.436 318.013 387.804 252.694 181.073 374.836 154.691 167.861 182.739 127.778 199.795 87.750 380.734 110.755 395.831 319.135 327.473 441.198 118.748 118.946 99.281 147.463 110.294 97.259 133.971 199.570 204.996 227.514 194.813 226.810 294.394 357.850 504.045 291.877 403.184 548.312 339.327 286.382 344.424 20-HETE 81.869 82.192 95.434 65.775 32.722 25.901 22.373 15.471 54.650 44.435 79.906 82.858 68.672 29.720 17.137 20.713 33.394 45.392 36.160 39.877 25.653 6.882 7.533 21.713 21.595 29.891 32.905 32.015 16.145 17.195 14.785 13.906 22.873 25.656 12.548 tetranor 12-HETE 13.491 9.731 20.397 12.156 3.448 7.191 4.878 4.831 12.788 8.447 5.779 17.131 16.287 15.022 5.435 6.423 5.270 5.330 5.164 6.724 3.822 3.641 5.793 4.400 3.321 5.011 4.453 2.874 1.767 6.896 6.809 5.482 5.658 8.064 4.775 3.806 2.999 4.271 3.394 3.980 3.727 1.598 2.379 1.928 2.337 2.882 3.140 3.881 4.588 4.673 5.183 6.081 2.906 12(S)-HHTrE 1.325 1.617 2.082 0.612 2.000 21.144 0.809 0.407 0.283 1.719 0.639 0.307 0.836 0.280 0.390 1.883 1.342 0.671 0.490 0.315 0.678 0.622 0.597 0.740 0.504 3.314 2.042 0.880 6.004 0.707 0.645 5-HEPE 156.253 157.002 318.154 240.517 43.850 32.584 52.419 27.898 183.206 96.226 165.482 373.636 293.345 248.677 3266.355 2706.711 3112.492 2996.388 3278.938 2661.062 1670.639 3502.173 5158.418 3571.465 3914.326 3726.217 4565.272 3974.489 1501.964 3748.628 1647.180 3483.473 1926.647 2258.726 3597.443 3269.260 4238.355 3846.750 3403.681 3121.545 2381.971 3044.050 2528.372 2829.643 2316.301 2273.531 2180.278 2218.641 2238.680 3751.223 3050.865 3479.686 1547.761 2974.934 2798.712 2967.013 8-HEPE 60.240 68.184 151.977 62.448 18.113 7.931 21.074 9.754 52.635 36.334 46.091 235.857 190.974 146.343 1082.003 1218.513 887.432 1258.614 1496.603 1402.197 753.249 1214.495 1699.841 1549.392 1425.670 1493.363 1515.625 1509.470 505.242 1557.868 342.002 1419.164 1109.188 1117.838 1714.255 1169.307 1458.129 1472.528 1226.715 770.577 1152.528 633.743 613.759 527.590 687.681 912.949 1239.080 1229.315 860.897 1215.291 1332.979 768.926 856.966 1265.698 1289.849 9-HEPE 44.872 41.712 94.124 39.950 12.918 5.313 38.806 28.608 27.501 140.983 145.042 101.557 872.352 1000.994 731.189 1090.021 1126.938 1028.229 595.233 1068.547 1417.962 1410.564 1229.042 1341.584 1326.134 1252.291 416.763 1222.281 349.486 1218.670 1036.803 1019.708 1280.446 928.782 1433.035 1081.369 1230.567 1072.636 952.659 849.060 592.184 564.957 499.551 613.822 811.387 1156.573 1079.958 774.312 1075.886 1130.138 570.768 686.723 1028.482 991.088 11-HEPE 168.928 156.560 366.256 153.562 58.330 24.372 56.977 28.008 142.643 97.884 94.773 559.769 507.393 365.119 2206.426 2780.538 1753.460 2491.124 3159.743 2813.975 1540.250 2266.671 3460.135 2531.035 3051.621 2793.501 2712.815 853.904 3731.939 756.911 2793.432 2644.785 2629.278 3354.197 2389.692 2823.148 2465.169 2248.860 2305.969 2110.859 1436.589 1398.713 1146.999 1414.502 1920.863 2920.405 3149.914 1868.874 2551.118 2621.721 1424.540 1882.094 2532.164 2782.824 12-HEPE 111.068 97.744 227.577 86.426 39.514 95.578 36.116 40.992 85.040 72.101 48.515 302.665 277.222 222.075 1350.329 1934.765 1012.192 1665.694 1914.606 1835.298 1238.659 1541.811 2951.484 2361.492 2112.797 2184.830 2142.710 1786.891 550.401 2153.098 761.766 2100.281 2144.496 3342.598 2133.386 2018.056 2137.317 1700.051 1629.612 2124.763 3470.359 2686.303 935.325 920.762 724.696 1340.895 1245.722 2031.314 2502.736 2386.163 2633.557 2638.176 911.075 1496.544 1803.308 1883.911 15(S)-HEPE 199.979 192.660 401.905 178.324 79.922 45.436 79.451 36.113 185.013 141.285 116.804 623.694 600.397 456.617 2204.515 2477.009 1864.824 2392.274 3081.529 2461.832 1776.924 2213.467 3272.194 2484.984 2742.442 2643.244 3106.963 3003.337 975.617 2598.722 830.723 2583.047 2737.274 2361.558 3431.703 2036.637 4080.031 2277.996 2733.963 2769.801 2260.174 2146.467 1413.474 1530.198 1271.458 1536.742 2212.016 2793.257 2800.954 1861.791 2371.802 2463.381 1362.633 1923.150 2957.745 2567.323 18-HEPE 96.691 85.123 199.051 75.964 31.603 17.054 38.314 22.086 90.857 63.304 56.198 251.367 230.555 178.502 1091.685 1307.192 845.470 1158.450 1279.000 1224.930 789.892 1044.094 1491.355 1308.321 1224.352 1417.384 1329.657 1243.948 471.495 1401.100 419.561 1281.689 1071.611 1136.810 1374.512 1009.812 1373.617 1199.305 1247.482 1062.707 960.937 1063.813 597.880 641.475 518.404 646.523 908.642 1262.968 1335.642 900.651 1153.047 1187.210 614.013 834.940 1108.115 1184.504 4-HDoHE 1903.242 1785.007 2569.999 2089.918 691.820 328.024 656.561 129.728 1733.103 1051.122 1253.341 1970.569 1966.892 1563.551 1913.839 2050.781 2710.158 1963.624 1890.553 1721.021 1092.138 928.809 1881.933 1236.566 1393.604 1422.394 935.472 1099.568 580.542 2307.988 884.148 2306.402 1320.400 1132.922 2138.425 1242.640 985.115 1223.936 1314.775 807.257 629.755 1059.400 1941.173 2606.111 2412.004 1532.459 1608.975 1413.161 1840.802 2497.150 1668.283 2235.742 1107.234 1859.031 1409.177 1957.073 7-HDoHE 72.060 65.110 112.417 77.845 27.329 9.283 15.810 6.229 49.111 33.273 34.782 136.086 98.354 71.151 114.676 162.920 102.615 130.452 143.358 169.348 60.474 54.040 99.443 65.829 57.987 74.246 54.808 64.341 20.858 113.036 26.605 135.159 121.870 76.581 147.497 52.961 60.682 41.820 67.196 38.995 37.117 47.581 74.652 73.471 82.744 48.276 75.698 114.788 158.600 79.477 107.872 76.532 98.097 60.904 81.208 113.082 8-HDoHE 220.685 174.590 388.953 200.491 69.983 29.706 57.393 19.141 142.176 104.685 83.579 331.417 289.964 197.689 274.865 381.097 225.621 305.755 311.881 375.861 160.418 135.039 221.747 156.203 145.289 179.953 132.944 136.144 48.169 303.844 57.822 321.740 315.224 211.640 390.843 128.882 132.321 103.452 135.417 90.350 91.724 126.576 208.630 194.740 199.786 136.099 194.482 335.262 424.702 224.579 251.931 227.019 206.265 158.465 208.285 258.242 10-HDoHE 396.826 305.030 608.734 379.125 168.154 49.346 124.862 37.113 287.758 206.009 184.248 643.284 594.101 434.254 703.051 894.855 587.104 919.335 951.879 1031.273 446.316 346.189 776.304 502.209 437.426 500.868 373.756 456.928 110.246 711.275 148.994 959.871 704.002 497.673 1040.808 349.816 474.864 347.780 487.804 300.473 220.760 296.320 477.510 484.007 569.145 370.477 534.951 731.341 897.009 541.227 561.940 623.024 426.671 492.007 616.622 636.881 11-HDoHE 339.201 275.396 546.002 357.300 160.429 65.437 99.029 31.500 240.281 202.008 114.668 562.870 519.796 359.718 475.605 643.360 414.566 513.085 550.969 737.152 310.943 234.500 620.913 273.309 263.074 327.879 229.110 309.885 66.799 466.897 101.121 551.154 511.029 390.480 614.476 253.156 246.541 210.810 287.321 187.120 160.837 205.603 390.060 354.492 338.078 294.276 371.970 500.328 729.966 642.718 413.930 495.775 306.477 308.698 393.649 447.906 13-HDoHE 551.622 364.087 856.357 377.167 250.085 88.986 174.717 53.241 400.858 299.078 176.636 778.053 776.008 517.740 846.289 1032.762 616.712 1039.251 1033.671 1243.279 599.127 393.653 884.565 556.005 475.194 571.915 428.233 498.876 71.605 946.584 135.761 1037.086 921.742 698.262 1143.265 344.464 467.198 349.552 496.500 355.246 258.326 381.316 527.524 536.427 536.607 490.043 544.907 897.238 1159.306 787.047 700.766 768.826 516.261 494.935 696.903 762.767 14-HDoHE 506.613 407.324 754.258 231.298 250.694 170.172 71.558 408.013 213.297 823.556 739.199 775.340 1079.938 741.036 1058.626 1111.347 1256.608 556.526 434.011 888.480 566.256 476.100 614.180 410.201 528.615 122.870 912.281 192.539 1026.710 866.603 648.407 1304.858 396.332 525.475 420.776 581.822 440.070 281.271 425.914 561.163 663.279 526.009 632.939 856.340 1150.528 770.672 718.556 771.503 485.349 560.331 752.769 796.246 16-HDoHE 583.777 413.367 930.405 509.996 259.753 94.356 186.690 63.892 491.869 341.032 209.877 910.068 828.630 583.696 875.092 1236.554 752.263 1141.666 1115.837 1435.007 677.537 466.054 825.284 536.082 511.625 572.213 445.674 519.829 142.299 905.539 171.334 1001.582 1067.034 831.289 1299.860 405.621 540.004 346.441 534.249 382.882 335.113 392.290 667.657 631.554 672.302 472.515 667.574 991.728 1459.142 694.804 793.649 645.879 660.114 511.754 737.647 845.437 17-HDoHE 110.425 80.764 163.081 79.444 45.633 41.189 30.636 10.996 72.442 53.435 29.990 164.098 139.716 92.624 128.713 200.295 109.769 184.906 157.590 246.696 110.311 64.624 122.345 86.148 72.003 94.250 69.940 81.988 11.274 126.328 23.540 157.824 181.352 123.062 209.299 49.512 78.280 48.365 68.191 58.512 56.227 58.616 87.144 87.611 89.386 71.111 102.176 149.200 209.367 99.491 110.734 100.439 97.183 75.311 115.544 131.079 20-HDoHE 266.584 178.275 406.955 185.916 100.129 37.293 75.641 28.987 186.517 126.206 67.997 397.456 286.517 247.100 336.157 516.197 264.224 441.972 404.838 515.957 277.196 165.623 269.995 208.276 183.492 245.356 160.914 198.594 53.393 372.993 76.703 390.550 401.255 290.082 483.381 159.858 170.690 135.498 201.875 134.756 132.429 150.775 218.619 213.165 213.436 176.634 233.133 412.320 580.904 263.633 289.742 276.134 249.384 190.917 265.763 338.248 9(10)-EpOME 10.433 3.945 4.974 3.130 7.491 10.617 2.316 2.659 2.274 2.216 6.019 2.547 4.662 1.243 3.229 2.798 6.437 6.915 1.549 3.891 3.182 7.952 2.160 1.227 4.818 3.006 4.512 8.007 4.302 1.914 1.665 1.426 3.408 3.602 5.273 14.105 14.486 13.872 7.835 6.826 24.150 8.689 7.950 2.202 1.980 2.101 4.110 4.851 12(13)-EpOME 4.093 1.464 1.370 2.837 1.637 4.320 1.019 1.519 2.919 3.554 1.656 2.693 5.186 4.042 0.792 4.305 1.452 1.910 3.014 9.239 8.245 8.977 4.707 4.408 11.952 3.756 4.447 4.906 4.296 5(6)-EpETrE 1.764 0.614 0.711 0.438 0.338 3.212 0.514 0.655 0.555 0.464 1.614 0.516 0.212 0.423 0.318 0.267 0.789 0.471 0.235 0.204 0.334 0.200 0.613 0.331 1.206 0.603 0.250 8(9)-EpETrE 1.430 1.784 1.280 1.147 1.238 2.083 1.939 1.229 1.377 1.786 0.713 0.685 0.430 0.726 1.160 1.449 1.452 1.245 11(12)-EpETrE 3.415 3.717 2.237 2.288 3.324 2.055 2.580 2.229 2.553 2.067 2.169 2.260 2.951 3.012 1.936 14(15)-EpETrE 3.784 2.009 1.542 5.179 0.445 8(9)-EpETE 0.094 0.092 0.211 0.048 0.118 0.041 0.158 0.278 0.123 0.185 2.618 2.522 3.120 3.123 2.110 3.328 0.991 2.488 5.071 4.811 2.746 3.667 3.194 4.485 1.163 2.753 1.374 3.903 1.676 1.507 3.063 2.214 4.899 3.809 5.279 2.981 2.225 2.919 2.340 2.268 2.793 2.059 2.227 1.841 2.991 2.974 1.406 2.367 2.632 3.112 11(12)-EpETE 9.151 9.636 22.124 9.963 2.894 1.549 3.660 2.016 9.809 7.182 5.983 35.974 31.710 23.923 240.531 248.203 192.471 332.559 347.665 378.942 140.216 284.345 399.526 340.391 335.851 338.353 376.887 99.032 318.002 71.111 328.677 265.185 280.871 368.446 221.170 428.473 292.780 415.902 301.518 240.565 245.754 175.034 124.782 138.095 158.561 219.271 350.512 276.316 161.454 306.010 251.073 149.660 188.596 251.561 272.838 14(15)-EpETE 2.158 2.177 3.816 2.596 0.855 0.959 1.235 0.491 1.523 1.160 1.454 5.231 5.515 3.775 24.902 26.419 19.167 38.515 42.221 33.861 42.060 55.815 36.451 39.702 40.419 42.895 9.240 7.895 37.149 33.029 29.678 44.113 53.820 32.358 53.512 30.391 27.752 25.639 16.437 11.858 14.337 22.102 36.070 34.483 17.158 33.237 27.506 17.012 28.727 29.203 17(18)-EpETE 3.069 2.840 0.916 2.108 1.954 1.544 1.696 3.123 2.729 2.945 7(8)-EpDPE 0.470 0.810 0.190 0.321 0.190 0.093 0.503 0.364 0.571 0.572 0.861 0.781 0.708 0.413 0.283 0.193 0.270 0.937 0.231 0.394 0.612 0.590 0.709 0.676 0.696 10(11)-EpDPE 0.257 1.407 0.402 0.141 0.449 0.509 0.325 0.146 0.379 0.218 0.423 0.599 1.538 0.805 13(14)-EpDPE 0.429 0.904 16(17)-EpDPE 0.328 0.097 19(20)-EpDPE 0.176 0.708 0.185 0.445 0.401 0.214 1.263 0.656 0.721 1.387 2.098 1.214 0.560 0.197 1.369 0.506 1.487 9,10-DiHOME 8.322 3.545 2.692 1.470 1.709 2.566 2.715 2.245 0.963 0.942 1.778 1.546 3.653 2.979 1.269 2.638 0.732 2.231 2.834 2.973 3.934 1.111 1.355 2.484 2.189 3.153 3.215 1.092 1.026 2.784 1.156 2.921 3.392 4.038 2.460 1.385 1.261 0.803 1.244 1.291 1.957 2.379 3.644 3.279 2.592 2.503 2.424 5.436 4.055 2.246 3.286 3.017 2.315 3.818 2.280 3.890 12,13-DiHOME 8.795 3.953 3.308 1.886 3.261 3.722 3.404 3.835 1.639 2.133 2.726 2.624 4.265 3.181 2.074 3.452 1.249 2.604 2.947 3.034 4.611 2.093 2.335 3.328 2.985 4.411 4.008 1.559 1.043 3.341 1.720 3.104 4.075 5.193 3.104 2.072 2.005 1.205 1.942 2.255 3.236 3.128 5.311 5.429 4.097 4.263 4.493 8.249 6.235 4.370 6.925 4.863 3.921 6.550 3.448 5.141 5,6-DiHETrE 1.360 1.059 1.081 1.097 0.491 0.942 0.790 1.175 0.807 0.840 1.024 0.967 1.255 1.098 0.666 0.798 0.568 0.468 0.380 0.466 0.361 0.168 0.305 0.216 0.178 0.368 0.190 0.145 0.135 0.407 0.295 0.371 0.290 0.421 0.359 0.166 0.143 0.133 0.195 0.120 0.131 0.183 0.421 0.393 0.382 0.338 0.286 0.272 0.339 0.541 0.512 0.432 0.216 0.511 0.287 0.341 8,9-DiHETrE 0.402 0.494 0.228 0.170 0.188 0.326 0.213 0.233 0.288 0.306 0.277 0.229 0.313 0.278 0.124 0.157 0.137 0.101 0.074 0.113 0.134 0.094 0.081 0.076 0.040 0.090 0.062 0.053 0.110 0.126 0.066 0.154 0.192 0.092 0.082 0.030 0.030 0.043 0.041 0.034 0.029 0.102 0.104 0.098 0.050 0.128 0.064 0.081 0.207 0.193 0.105 0.079 0.124 0.062 0.063 11,12-DiHETrE 4.107 3.554 1.258 0.656 0.939 1.748 1.156 1.631 2.019 2.185 1.112 1.594 1.182 1.723 0.848 1.101 1.084 0.755 0.738 0.841 0.648 0.634 0.471 0.542 0.346 0.439 0.315 0.315 0.371 0.547 0.438 0.472 1.589 1.132 0.671 0.504 0.222 0.179 0.233 0.182 0.234 0.146 0.764 0.648 0.477 0.297 0.821 0.421 0.490 1.240 1.542 0.540 0.352 0.804 0.407 0.462 14,15-DiHETrE 10.813 10.391 4.625 3.340 4.665 6.671 5.248 6.926 6.417 8.143 6.794 5.429 6.619 5.606 4.023 3.316 4.218 2.787 2.924 3.281 2.824 2.892 2.520 2.622 1.640 2.526 2.138 1.715 1.345 2.876 2.870 2.520 6.067 5.011 3.058 2.902 1.295 1.005 1.735 1.191 1.425 1.020 3.509 2.908 3.165 1.769 3.033 2.483 2.613 6.414 6.857 2.742 1.885 2.991 1.720 2.046 5,6-DiHETE(EPA) 0.176 0.110 0.032 0.298 0.079 0.066 0.081 19,20-DiHDoPE 2.590 2.086 1.417 0.836 0.694 1.264 1.026 0.711 1.166 1.063 1.019 1.191 1.242 1.235 2.019 3.299 2.030 3.517 2.920 3.254 1.725 1.531 3.051 2.709 1.926 3.183 2.168 2.173 0.671 3.260 0.988 3.071 2.606 3.107 2.600 1.555 2.416 1.624 2.246 1.419 1.116 1.688 1.711 1.428 1.726 1.240 1.512 1.623 2.755 2.426 3.017 2.080 1.272 1.695 2.260 2.355 9-OxoODE 247.945 73.798 192.743 88.208 43.597 49.441 57.027 39.540 23.836 25.420 37.445 199.195 353.797 224.531 178.441 292.623 120.880 308.841 331.136 359.076 143.559 83.252 263.289 200.593 162.955 344.877 324.819 182.164 16.272 317.650 86.237 344.411 300.797 302.801 185.393 148.845 289.741 207.210 185.425 204.095 126.464 241.218 89.740 86.060 80.922 114.726 114.030 280.183 276.143 307.281 226.255 233.777 196.639 107.169 240.904 198.617 13-OxoODE 565.830 212.773 483.739 231.402 106.985 97.785 123.166 77.663 68.034 52.011 75.925 503.794 824.633 541.682 376.268 574.547 259.410 571.347 570.776 635.272 320.725 169.019 401.842 394.116 306.063 668.888 611.570 340.448 35.834 631.479 154.111 633.459 625.196 534.330 406.701 288.121 409.068 385.825 381.128 393.650 214.143 409.666 192.163 187.132 173.838 216.183 243.267 640.104 574.448 420.591 377.105 385.028 397.571 203.222 464.627 384.247 9-OxoOTrE 18.169 4.669 14.050 5.224 2.214 2.489 3.569 2.998 1.368 1.510 1.832 11.981 22.455 14.495 13.364 16.504 8.282 24.200 24.126 30.158 12.448 4.722 17.658 19.319 13.178 30.910 24.874 15.020 0.959 30.503 5.708 31.717 27.140 25.078 14.174 12.759 27.510 16.709 15.205 19.603 11.479 22.625 3.433 2.385 2.715 8.851 10.308 21.801 17.873 9.400 16.286 16.435 4.872 5.790 20.102 14.030 15-OxoEDE 1.573 0.385 0.648 0.377 0.329 0.249 0.152 1.031 1.906 1.412 0.731 1.280 0.548 1.733 1.170 0.501 0.588 0.680 0.475 0.482 1.035 0.738 0.440 1.131 0.141 1.166 1.583 1.432 0.799 0.435 0.513 0.456 0.352 0.504 0.353 0.618 0.266 0.330 0.429 0.754 1.060 0.938 0.995 0.844 0.220 0.506 0.929 0.798 5-oxoETE 51.897 50.764 55.472 73.317 19.860 16.437 20.385 13.151 27.766 18.019 31.087 49.644 96.158 41.312 28.161 28.170 22.358 21.396 25.211 22.055 12.592 7.239 23.787 9.999 8.644 14.578 9.605 11.328 6.162 24.096 14.463 27.747 21.100 19.246 15.202 10.973 15.945 17.800 12.160 6.915 4.879 13.559 17.166 19.133 20.948 15.508 12.819 16.061 18.391 53.846 24.677 33.196 20.775 42.911 27.333 18.328 12-OxoETE 15-OxoETE 4.345 3.939 6.165 3.945 2.204 2.287 2.621 0.916 1.979 2.039 2.531 5.534 8.941 5.628 14.615 16.042 11.164 16.384 18.555 17.266 8.772 15.317 20.490 22.162 18.323 21.039 20.947 18.463 6.562 19.707 7.086 19.081 17.819 15.089 24.611 11.833 23.294 16.214 19.171 13.460 17.073 10.583 9.839 8.941 7.155 7.672 12.219 16.726 17.456 11.427 17.946 15.768 9.385 9.677 13.926 11.831 LXA4 4.028 4.642 5.670 7.263 1.003 0.468 1.219 0.225 4.484 1.526 4.636 4.758 7.990 5.009 1.729 2.213 2.672 2.085 2.972 0.685 1.421 1.091 3.458 0.928 1.087 1.528 1.368 1.047 0.792 3.742 1.036 2.585 0.820 1.854 1.574 1.291 0.844 0.790 1.736 0.423 0.336 1.104 1.869 1.684 4.150 1.704 1.304 1.477 1.291 3.085 1.900 3.598 2.289 3.274 1.781 2.817 15-epi LXA4 0.020 0.063 15-oxo LXA4 0.329 0.149 0.372 0.734 0.612 1.012 0.903 0.161 0.499 0.353 0.243 0.372 0.147 0.183 0.233 0.216 0.279 0.509 0.493 0.585 0.339 0.496 LXA5 0.079 0.041 0.081 0.099 0.017 0.032 0.078 0.089 0.173 0.113 0.907 0.642 1.452 1.068 1.062 1.031 0.493 0.928 3.400 2.412 1.506 3.467 2.822 2.759 0.470 1.870 0.993 1.548 0.608 0.956 0.798 2.204 1.514 2.327 2.687 1.436 0.726 1.577 0.797 0.747 1.124 1.094 0.919 0.769 0.676 2.710 1.332 1.813 0.688 2.088 1.526 1.228 LXB4 0.388 0.813 0.104 0.269 0.217 0.156 0.272 0.114 0.489 RvD1 0.992 0.385 1.155 1.460 0.821 0.470 0.885 1.503 0.913 1.072 3.409 4.105 1.331 3.246 1.025 0.686 2.324 1.782 1.781 0.903 1.681 1.076 1.862 1.690 1.386 3.020 0.975 0.976 1.440 1.455 3.008 1.914 3.992 1.025 1.742 RvD2 0.309 0.621 RvD3 5.039 3.519 2.917 5.236 4.985 2.391 3.930 6.781 13.277 AT-RvD3 0.213 0.737 0.340 0.608 RvD4 0.366 0.325 0.274 0.342 0.372 0.124 0.446 0.247 0.441 0.357 0.145 0.458 0.229 0.130 0.384 0.437 0.282 0.273 0.335 RvD5 RvD6 (4,17-DiHDoHE) 0.438 0.097 0.314 0.120 0.103 0.127 0.120 0.113 0.113 0.429 0.797 0.335 0.480 0.783 0.324 1.157 0.844 1.121 0.286 0.157 0.563 0.506 0.279 1.059 0.622 0.485 0.664 0.135 0.772 1.069 0.868 0.410 0.488 0.268 0.221 0.376 0.282 0.399 0.580 0.239 0.424 0.312 0.304 0.906 1.476 1.182 0.925 0.577 0.274 0.154 0.404 0.490 8-oxoRvD1 0.088 0.056 17-oxoRvD1 RvD5(n-3DPA) (7,17-DiHDoPE) 0.098 0.041 0.097 0.420 0.651 0.641 0.577 0.687 0.881 0.284 0.422 1.023 0.635 0.735 0.517 0.391 0.502 0.253 1.131 0.149 0.960 0.358 0.595 0.841 0.314 0.910 0.891 0.950 0.728 0.250 0.425 0.276 0.623 0.309 0.207 0.510 0.279 0.518 0.473 0.366 0.439 0.862 0.673 RvE1 RvE2 0.223 0.269 0.465 0.481 0.037 0.011 0.040 0.220 0.106 0.297 0.716 0.634 0.554 5.061 4.969 6.325 6.793 7.461 6.190 2.653 6.778 14.394 9.009 8.672 9.351 7.229 10.069 3.890 9.545 3.512 7.876 3.293 5.624 6.188 5.790 9.081 7.371 9.111 5.219 3.133 5.939 4.075 4.322 7.075 4.629 3.973 3.706 4.861 6.809 6.801 7.399 4.888 8.952 7.409 7.871 RvE3 0.257 0.385 0.374 0.227 2.112 3.129 2.602 4.261 4.551 3.684 2.948 4.617 11.531 6.907 4.994 6.631 6.729 0.680 3.862 1.235 3.620 2.491 3.733 2.537 3.872 6.432 8.971 6.275 3.453 2.265 3.295 1.775 1.067 1.372 1.218 2.528 3.601 3.940 4.192 4.879 3.029 2.750 3.893 3.455 PD1 16.200 14.884 26.109 25.365 3.369 0.538 2.114 0.345 13.354 5.490 4.715 27.940 26.592 18.581 20.003 37.928 24.294 35.033 36.678 40.426 17.533 13.393 28.480 17.838 15.506 20.371 11.760 16.306 5.501 31.255 5.168 34.966 23.522 23.929 38.693 12.447 18.625 22.201 27.591 14.356 6.644 13.524 19.577 15.345 28.633 14.804 15.488 19.770 30.342 20.269 24.584 20.265 32.971 16.417 26.006 26.923 AT-PD1 0.139 0.141 PD1(n-3, DPA) 1.847 1.729 3.054 2.916 0.363 1.237 0.450 0.630 3.584 3.874 3.448 9.226 15.040 9.670 17.162 18.131 17.669 8.624 9.744 24.588 18.083 13.384 15.125 12.292 16.699 3.954 20.916 3.173 19.686 11.059 16.191 19.853 9.464 27.444 33.217 25.127 18.198 5.294 10.543 6.958 6.033 11.725 7.900 5.845 7.915 12.880 6.484 13.158 13.458 9.123 10.088 17.634 15.594 10S,17S-DiHDoHE 44.231 47.893 84.046 57.229 11.403 3.289 6.964 1.519 43.332 17.968 15.464 74.921 79.814 54.150 57.359 109.514 54.755 106.340 96.905 104.796 36.466 38.692 90.976 47.458 38.290 40.789 30.839 38.598 12.555 75.601 13.722 97.514 69.752 62.410 99.556 32.461 34.613 34.094 30.880 24.361 15.383 34.790 46.126 36.854 54.608 35.823 37.812 55.171 76.782 43.525 52.567 46.433 87.402 58.176 52.421 70.400 22-OH-PD1 Maresin1 2.770 3.370 6.041 0.435 1.536 1.862 7.804 4.220 4.842 8.169 6.202 8.784 4.020 3.206 4.626 3.435 2.469 1.237 9.339 6.027 5.185 6.451 6.244 3.678 1.449 5.322 3.989 7.550 3.788 3.866 6.165 3.494 5.288 5.323 8.989 3.648 5.828 5.907 7(S)-Maresin1 2.277 3.929 1.919 0.787 4.250 5.680 6.973 7.093 3.321 3.677 3.075 1.188 5.363 0.803 7.435 4.279 7.811 7.829 6.902 6.253 3.887 1.247 4.389 2.546 2.233 4.428 5.168 4.143 5.766 2.954 5.035 MaR1(n-3DPA) 4.809 3.842 7.988 5.677 0.925 3.832 1.338 11.904 4.816 8.309 23.878 47.734 25.090 43.807 39.330 60.955 21.993 22.161 58.616 52.158 33.100 32.986 26.777 28.736 9.168 65.737 4.440 64.695 24.639 29.330 63.604 18.745 71.192 71.319 77.611 45.370 10.132 25.001 14.550 16.641 25.746 13.860 18.091 17.878 29.208 10.776 28.868 38.030 25.076 22.239 48.255 40.611 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name KEGG ID PubChem ID quantified m/z 13,14dhPGE1 161273 356 13,14dh-15k-PGE1 16061097 372 D17-PGE1 5283114 352 PGE1 C04741 7312 354 15(R)-PGE1 5283056 354 15-keto PGE1 C04654 5280710 352 Bicyclo PGE1 5283055 338 19(R)-hydroxy PGE1 5283115 370 2,3-dinor PGE1 16061101 326 PGE2 C00584 5280360 352 15-keto PGE2 C04707 5280719 350 13,14dh-15k-PGE2 C04671 5280711 352 Bicyclo PGE2 137699601 334 PGA2 C05953 5280880 334 tetranor PGEM 161468 328 PGE3 C06439 5280937 350 PGD2 C00696 448457 352 PGJ2 C05957 5280884 334 D12-PGJ2 C05958 5280885 334 15d-D12,14-PGJ2 C14717 5311211 316 13,14dh-15k-PGD2 5283036 352 PGD3 C13802 5282260 350 15d-D12,14-PGJ3 PGF1a C06475 5280939 356 PGF2a C00639 5280363 354 15-keto PGF2a C05960 5280887 352 13,14dh-15k-PGF2a 5283039 354 PGF3a C06476 5280940 352 iPF-VI 42607309 354 6kPGF1a C05961 5280888 370 6-keto PGE1 C05962 5280889 368 6,15-diketo PGFa 174013 370 TXB2 C05963 5283137 370 11dh-TXB2 C05964 5280891 368 2,3-dinor TXB2 5283138 342 11dh-2,3-dinor TXB2 35024530 340 TXB3 5283140 368 11dh TXB3 16061115 366 LTB4 C02165 5280492 336 12-OxoLTB4 5283130 334 20-hydroxy LTB4 C04853 5280745 352 20-COOH LTB4 C05950 5280877 366 18-carboxy dinor LTB4 6438938 338 LTB5 5283125 334 5(S),6(S)-DiHETE 5283161 336 5(S),12(S)-DiHETE 9997164 336 5(S),15(S)-DiHETE 5283158 336 8(S),15(S)-DiHETE 5283183 336 5(S),15(S)-DiHEPE 5283180 368 9-HODE 5283944 296 13-HODE C14762 6443013 296 9(S)-HOTrE C16326 6439873 294 13(S)-HOTrE C16316 16061072 294 13(S)-HOTrE(g) 5282971 294 11(R)-HEDE 16061090 324 15(S)-HEDE 5282705 324 8(S)-HETrE 5283148 322 5(S)-HETrE 5283143 322 5-HETE C04805 5280733 320 8-HETE C14776 5283154 320 9-HETE 14123398 320 11-HETE 5312982 320 12-HETE C14777 5283155 320 15-HETE 9966861 320 20-HETE C14748 5283157 320 tetranor 12-HETE 5282970 266 12(S)-HHTrE 5283141 280 5-HEPE 6439678 318 8-HEPE 16061128 318 9-HEPE 16061129 318 11-HEPE 16061130 318 12-HEPE 10041593 318 15(S)-HEPE 16061131 318 18-HEPE 16061132 318 4-HDoHE 14429109 344 7-HDoHE 16061142 344 8-HDoHE 11976798 344 10-HDoHE 11537494 344 11-HDoHE 11631564 344 13-HDoHE 11559259 344 14-HDoHE 11566378 344 16-HDoHE 11595378 344 17-HDoHE 6439179 344 20-HDoHE 16061143 344 9(10)-EpOME C14825 6246154 296 12(13)-EpOME C14826 5356421 296 5(6)-EpETrE C14768 5283202 320 8(9)-EpETrE C14769 5283203 320 11(12)-EpETrE C14770 5283204 320 14(15)-EpETrE C14771 5283205 320 8(9)-EpETE 16061085 318 11(12)-EpETE 16061087 318 14(15)-EpETE 16061088 318 17(18)-EpETE C13843 16061089 318 7(8)-EpDPE 11653103 344 10(11)-EpDPE 11638767 344 13(14)-EpDPE 11674605 344 16(17)-EpDPE 14392758 344 19(20)-EpDPE 11631565 344 9,10-DiHOME 5282958 314 12,13-DiHOME 5282961 314 5,6-DiHETrE C14772 5283142 338 8,9-DiHETrE C14773 5283144 338 11,12-DiHETrE C14774 5283146 338 14,15-DiHETrE C14775 5283147 338 5,6-DiHETE(EPA) 14429105 336 19,20-DiHDoPE 16061148 362 9-OxoODE 5283011 294 13-OxoODE C14765 6446027 294 9-OxoOTrE 11380794 292 15-OxoEDE 5283013 322 5-oxoETE C14732 5283159 318 12-OxoETE C14807 5283162 318 15-OxoETE C04577 5280701 318 LXA4 C06314 5280914 352 15-epi LXA4 9841438 352 15-oxo LXA4 5221886 350 LXA5 6439927 350 LXB4 C06315 5280915 352 RvD1 16126783 376 RvD2 53477504 376 RvD3 53477497 376 AT-RvD3 44251573 376 RvD4 53477505 376 RvD5 25073195 360 RvD6 (4,17-DiHDoHE) 25073193 360 8-oxoRvD1 53477507 374 17-oxoRvD1 44576257 374 RvD5(n-3DPA) (7,17-DiHDoPE) RvE1 C18171 10473088 350 RvE2 C18173 16061125 334 RvE3 56848721 334 PD1 16042541 360 AT-PD1 24778497 360 PD1(n-3, DPA) 86288884 362 10S,17S-DiHDoHE 11667655 360 22-OH-PD1 Maresin1 60201795 360 7(S)-Maresin1 42607314 360 MaR1(n-3DPA) 132472313 362 METABOLITES_END #END